<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="74212"><DrugName>PIM-447</DrugName><DrugSynonyms><Name><Value>LGH-477</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>LGH-447</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PIM-447</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="23137">Novartis AG</CompanyOriginator><CompaniesSecondary><Company id="23137">Novartis AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="74212" type="Drug"><TargetEntity id="753172" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="1272" type="ciIndication"><TargetEntity id="D46" type="ICD10"></TargetEntity><TargetEntity id="10028533" type="MEDDRA"></TargetEntity><TargetEntity id="D011289" type="MeSH"></TargetEntity><TargetEntity id="-376765165" type="omicsDisease"></TargetEntity><TargetEntity id="711" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1731" type="ciIndication"><TargetEntity id="D015470" type="MeSH"></TargetEntity><TargetEntity id="519" type="ORPHANET"></TargetEntity><TargetEntity id="-1550871001" type="omicsDisease"></TargetEntity><TargetEntity id="686" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"></TargetEntity><TargetEntity id="10028228" type="MEDDRA"></TargetEntity><TargetEntity id="D009101" type="MeSH"></TargetEntity><TargetEntity id="29073" type="ORPHANET"></TargetEntity><TargetEntity id="-18870694" type="omicsDisease"></TargetEntity><TargetEntity id="710" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2436" type="ciIndication"><TargetEntity id="D75.81" type="ICD10"></TargetEntity><TargetEntity id="10028537" type="MEDDRA"></TargetEntity><TargetEntity id="D055728" type="MeSH"></TargetEntity><TargetEntity id="-1044236653" type="omicsDisease"></TargetEntity><TargetEntity id="1634" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="4528" type="Action"><TargetEntity id="3101" type="Mechanism">Pim-1 Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4526" type="Action"><TargetEntity id="3213" type="Mechanism">Pim-3 Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4524" type="Action"><TargetEntity id="3212" type="Mechanism">Pim-2 Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="4522" type="Action"><TargetEntity id="3211" type="Mechanism">Pim Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01207" type="ciTarget"><TargetEntity id="10006318274151163" type="siTarget">Serine/threonine-protein kinase pim-3</TargetEntity><TargetEntity id="-635824581" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01570" type="ciTarget"><TargetEntity id="190103944952923" type="siTarget">Serine/threonine-protein kinase pim-1</TargetEntity><TargetEntity id="622" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01571" type="ciTarget"><TargetEntity id="844491480110403" type="siTarget">Serine/threonine-protein kinase pim-2</TargetEntity><TargetEntity id="-369086443" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1272">Myelodysplastic syndrome</Indication><Indication id="1731">Acute myelogenous leukemia</Indication><Indication id="1828">Multiple myeloma</Indication><Indication id="2436">Myelofibrosis</Indication></IndicationsSecondary><ActionsPrimary><Action id="4526">PIM-3 protein kinase inhibitor</Action><Action id="4528">PIM-1 protein kinase inhibitor</Action><Action id="4522">PIM protein kinase inhibitor</Action><Action id="4524">PIM-2 protein kinase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1589">Apoptosis stimulator</Action><Action id="62255">Anticancer protein kinase inhibitor</Action><Action id="7293">Synergist</Action><Action id="767">Cell cycle inhibitor</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-03-28T11:31:12.000Z</LastModificationDate><ChangeDateLast>2018-03-12T00:00:00.000Z</ChangeDateLast><AddedDate>2011-10-24T12:09:05.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt; was developing PIM-447 (formerly LGH-447), a pan-PIM protein 1, 2, and 3 kinase inhibitor, for the potential oral treatment of hematological tumors, including multiple myeloma (MM),  acute myeloid leukemia (AML), high risk myelodysplastic syndrome (MDS), and myelofibrosis (MF) [&lt;ulink linkID="1232776" linkType="Reference"&gt;1232776&lt;/ulink&gt;], [&lt;ulink linkID="1338794" linkType="Reference"&gt;1338794&lt;/ulink&gt;], [&lt;ulink linkID="1438563" linkType="Reference"&gt;1438563&lt;/ulink&gt;],  [&lt;ulink linkID="1534352" linkType="Reference"&gt;1534352&lt;/ulink&gt;], [&lt;ulink linkID="1655471" linkType="Reference"&gt;1655471&lt;/ulink&gt;], [&lt;ulink linkID="1681940" linkType="Reference"&gt;1681940&lt;/ulink&gt;], [&lt;ulink linkID="2004756" linkType="Reference"&gt;2004756&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2014, a phase Ib/II trial of PIM-447 in combination with &lt;ulink linkID="65353" linkType="Drug"&gt;alpelisib&lt;/ulink&gt; for MM was initiated; in January 2016, the trial was completed [&lt;ulink linkID="1579001" linkType="Reference"&gt;1579001&lt;/ulink&gt;]. In March 2014, a phase I trial in AML and MDS began [&lt;ulink linkID="1534352" linkType="Reference"&gt;1534352&lt;/ulink&gt;]. In June 2015, a phase I trial of PIM-447 in combination with &lt;ulink linkID="54662" linkType="Drug"&gt;ruxolitinib&lt;/ulink&gt; and &lt;ulink linkID="65360" linkType="Drug"&gt;LEE-011&lt;/ulink&gt; in MF patients was initiated  [&lt;ulink linkID="1655471" linkType="Reference"&gt;1655471&lt;/ulink&gt;]. In April 2017, regulatory filings for hematological tumors were expected in 2021 or later [&lt;ulink linkID="1921373" linkType="Reference"&gt;1921373&lt;/ulink&gt;]. However, in January 2018, Novartis stated that development of the drug in hematological tumors had been discontinued while being in exploratory development [&lt;ulink linkID="2004756" linkType="Reference"&gt;2004756&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In April 2017, regulatory filings for hematological tumors were expected in 2021 or later [&lt;ulink linkID="1921373" linkType="Reference"&gt;1921373&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Multiple myeloma&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In May 2014, a non-randomized, parallel group, open-label, phase Ib/II study (&lt;ulink linkID="189469" linkType="Protocol"&gt;NCT02144038&lt;/ulink&gt;, CLGH447X2103C, 2013-004959-21) to assess the safety and effectiveness of PIM-447 in combination with alpelisib was planned in patients with relapsed or refractory MM (expected n = 85) in the US, Australia, Germany, Italy,  and Singapore. The study was expected to begin later that month and complete in November 2016. In July 2014, the trial was initiated. In January 2016, the trial was completed [&lt;ulink linkID="1579001" linkType="Reference"&gt;1579001&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In May 2014, a multicenter, open-label, dose-escalation, phase I trial (&lt;ulink linkID="195800" linkType="Protocol"&gt;NCT02160951&lt;/ulink&gt;; CLGH447X1101) was planned to begin in Japan in September 2014, in patients with relapsed or refractory MM (expected n = 13). At that time, the trial was expected to complete in May 2016 [&lt;ulink linkID="1954913" linkType="Reference"&gt;1954913&lt;/ulink&gt;]. In October 2014, the trial was initiated [&lt;ulink linkID="1954913" linkType="Reference"&gt;1954913&lt;/ulink&gt;]. In August 2016, the trial was completed [&lt;ulink linkID="1954913" linkType="Reference"&gt;1954913&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2012, an open-label, phase I study (&lt;ulink linkID="81756" linkType="Protocol"&gt;NCT01456689&lt;/ulink&gt;; CLGH447X2101; EUDRACT 2011-003820-10) was initiated in patients with relapsed/refractory MM (expected n = 33) in the US, Singapore, Germany and Spain, to assess the safety, pharmacokinetics and pharmacodynamics of PIM-447. At that time, the study was scheduled to complete in August 2014 [&lt;ulink linkID="1232776" linkType="Reference"&gt;1232776&lt;/ulink&gt;]. In December 2013, data from this trial were presented at the 55th ASH Meeting in New Orleans, LA. As of 10 October, 2013, the dose-escalation phase of the study was ongoing at 500 mg qd. In half of the 30 patients receiving the study drug, duration of exposure was ten or more weeks. At that time, 12 patients were still receiving treatment across the 150- to 500-mg treatment groups and 18 patients had discontinued, the most common reason for this being disease progression. Dose-limiting toxicities included grade 3 thrombocytopenia (1 patient each in the 200-,250- and 350-mg treatment groups) and grade 3 fatigue ( 1patient, 500-mg group). At day 14, the estimated effective half life of PIM-447 was approximately 42 h at 350 mg [&lt;ulink linkID="1507409" linkType="Reference"&gt;1507409&lt;/ulink&gt;], [&lt;ulink linkID="1505152" linkType="Reference"&gt;1505152&lt;/ulink&gt;]. In December 2014, further clinical data were presented at the 56th ASH Meeting in San Francisco, CA. Thrombocytopenia (18.5%), anemia (18.5%), neutropenia (13%), and fatigue (11.1%) were most common grade-3/4 AEs. Overall, one very good partial response at 200 mg and four partial responses were reported at doses ranging from 150 to 500 mg.  PIM-447 was generally well tolerated [&lt;ulink linkID="1618653" linkType="Reference"&gt;1618653&lt;/ulink&gt;]. ​In April 2015, further results were presented at the 106th AACR meeting in Philadelphia, PA. Approximate dose-proportion increases in the exposure of PIM-447 were observed in the dose ranges 70 to 700 mg. MTD was determined to be 500 mg (qd). PIM-447 demonstrated durable single-agent activity at doses &amp;gt;/= 150 mg. Overall response rate, disease control rate and clinical benefit rate were 11, 72 and 21%, respectively. Overall, ten DLTs were reported [&lt;ulink linkID="1648891" linkType="Reference"&gt;1648891&lt;/ulink&gt;]. In August 2015, similar data were presented at the 250th ACS meeting in Boston, MA [&lt;ulink linkID="1681940" linkType="Reference"&gt;1681940&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Myelofibrosis&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In February 2015, a non-randomized, open-label, phase Ib study (&lt;ulink linkID="224046" linkType="Protocol"&gt;NCT02370706&lt;/ulink&gt;; CPIM447X2104C, 2014-003801-14) was planned to start later that month to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the triple combination of PIM-447 plus &lt;ulink linkID="54662" linkType="Drug"&gt;ruxolitinib&lt;/ulink&gt; and &lt;ulink linkID="65360" linkType="Drug"&gt;LEE-011&lt;/ulink&gt;, and for PIM-447 plus ruxolitinib, and LEE-011 plus ruxolitinib, in patients (estimated n = 92) in Australia, Canada, Europe and Singapore with MF. In June 2015, the trial was initiated. At that time, the trial was expected to complete in July 2018 [&lt;ulink linkID="1655471" linkType="Reference"&gt;1655471&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Myelodysplastic syndrome&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In January 2014, a non-randomized, single-group assignment, open-label, phase I trial (&lt;ulink linkID="176390" linkType="Protocol"&gt;NCT02078609&lt;/ulink&gt;; CLGH447X2102; 2013-003756-20) was planned to begin in March 2014 in patients (expected n = 27) with AML or high risk MDS in the US, Australia, Europe and Japan.   The primary endpoint was the incidence of dose-limiting toxicities. At that time, the trial was expected to complete in  November 2015. The study began in March 2014 [&lt;ulink linkID="1534352" linkType="Reference"&gt;1534352&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In August 2017, in vitro data were presented at the 254th ACS National Meeting and Exhibition in Washington DC. Against PIM 1, 2 and 3 kinases, PIM-447 exhibited Ki values of 0.001, 0.014 and 0.007 microM, respectively [&lt;ulink linkID="1952784" linkType="Reference"&gt;1952784&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2016, preclinical data were presented at the 58th ASH Annual Meeting and Exposition in San Diego, CA. In allografted Ba/f3 cells expressing EPOR-JAK2V617F, the combination of INC-424 and LEE-011 showed synergistic anti-tumor activity, when compared with single agents alone. Synergistic in vivo efficacy was observed with the combination of INC-424, PIM-447 and LEE-011, without additive toxicity [&lt;ulink linkID="1881337" linkType="Reference"&gt;1881337&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, preclinical data were presented at the 107th AACR Annual Meeting in New Orleans, LA, USA. In NCI-H929 and MM1-S cells, treatment with PIM-447 (1 microM) + lenalidomide (1 microM) combination showed synergistic reduction in c-MYC levels when compared with single agents alone. PIM-447 + lenalidomide synergy in reducing c-MYC levels was not mediated by reduction in gene tanscripition or protein stability [&lt;ulink linkID="1749015" linkType="Reference"&gt;1749015&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2015, preclinical data were presented at the 250th ACS meeting in Boston, MA. The Ki values of PIM-447 for PIM 1, 2, and 3 kinases were 6, 18, and 9 pM, respectively. The IC50 values ranged from 0.01 to 5 microM. The drug was active in a mouse model with multiple myeloma [&lt;ulink linkID="1681940" linkType="Reference"&gt;1681940&lt;/ulink&gt;]. In November 2015, similar data were published [&lt;ulink linkID="1899003" linkType="Reference"&gt;1899003&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, preclinical data were presented at the 106th AACR meeting in Philadelphia, PA. Combination of ruxolitinib, PIM-447 and LEE-011 showed 100% regression in UKE-1 (JAK2) xenograft tumor growth. In pSTAT5 modulation with INC-424 (65% inhibition), INC-424 + PIM-447 (63% inhibition) and increased inhibition was observed with combination of ruxolitinib, PIM-447 and LEE-011 (75% inhibition) and pBAD modulation with PIM-447 and INC-424 + PIM-447 with inhibition of 44 and 48%, respectively was observed [&lt;ulink linkID="1649483" linkType="Reference"&gt;1649483&lt;/ulink&gt;]. Further data were presented at the same conference. The triple combination of ruxolitinib, LGH-447 and LEE-011 showed efficacy against other JAKV617F mutant model [&lt;ulink linkID="1648718" linkType="Reference"&gt;1648718&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, preclinical data were presented at the 19th EHA Congress in Milan, Italy. In vivo, the triple combination of &lt;ulink linkID="58228" linkType="Drug"&gt;ruxolitinib&lt;/ulink&gt; + PIM-447 + &lt;ulink linkID="65360" linkType="Drug"&gt;LEE-011&lt;/ulink&gt; showed greater reductions in spleen size and produced marked reduction in JAK2 V617F allele burden [&lt;ulink linkID="1566967" linkType="Reference"&gt;1566967&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013, preclinical data were presented at the 55th ASH Meeting in New Orleans, LA. In various MM cell lines, PIM-447 induced apoptosis by cleavage of caspases 8, 9, 3 and 7 and PARP and it also reduced BAD activation and Bcl-XL expression. PIM-447 blocked the cell cycle in MM cells, as indicated by increase in G0-G1 and decrease in S-G2-M phases. PIM-447 potently reduced the expression of transcription factors involved in osteoclast differentiation/function and disrupted the F-actin ring integrity [&lt;ulink linkID="1504347" linkType="Reference"&gt;1504347&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013, preclinical data were presented at the 55th ASH Meeting in New Orleans, LA.  In JAK-mutant MPN and acute myeloid leukemia cell lines, the combination of PIM-447 and ruxolitinib showed synergistic cell growth inhibition. In Ba/F3-JAK2V617F MPN model, PIM-447 along with ruxolitinib significantly reduced spleen weight when compared with PIM-447 and ruxolitinib alone and inhibited pMEK and pSTAT5 which was comparable to that of ruxolitinib [&lt;ulink linkID="1504323" linkType="Reference"&gt;1504323&lt;/ulink&gt;]. In April 2014,  further data were presented at the 105th AACR meeting in San Diego, CA. In Ba/F3-EPOR-JAK2V617F model, the triple combination of ruxolitinib + PIM-447 + LEE-011 exhibited greater reduction of tumor load and spleen size and also exhibited &amp;gt; 80% of down-modulation of JAK2V617F allele burden in BaF MPN model [&lt;ulink linkID="1538746" linkType="Reference"&gt;1538746&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013, preclinical data were presented at the 55th ASH Meeting in New Orleans, LA.  In SCID/bg mice implanted with KMS-11.luc multiple myeloma xenograft, PIM-447 treatment resulted in significant tumor growth inhibition with moderate body weight loss.  In the KG-1 subcutaneous AML xenografts model, PIM-447 showed dose-dependent tumor growth inhibition. PIM-447 in combination with &lt;ulink linkID="65353" linkType="Drug"&gt;BYL-719&lt;/ulink&gt; and &lt;ulink linkID="70185" linkType="Drug"&gt;cytarabine&lt;/ulink&gt; showed greater efficacy in MM KMS-12BM tumor model and KG-1 mouse AML model, respectively [&lt;ulink linkID="1502772" linkType="Reference"&gt;1502772&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2436">Myelofibrosis</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2436">Myelofibrosis</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2436">Myelofibrosis</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2436">Myelofibrosis</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2018-01-24T00:00:00.000Z</StatusDate><Source id="2004756" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2012-05-03T00:00:00.000Z</StatusDate><Source id="1232776" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2012-05-03T00:00:00.000Z</StatusDate><Source id="1232776" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2014-01-31T00:00:00.000Z</StatusDate><Source id="1534352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2014-01-31T00:00:00.000Z</StatusDate><Source id="1534352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2014-01-31T00:00:00.000Z</StatusDate><Source id="1534352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2014-01-31T00:00:00.000Z</StatusDate><Source id="1534352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2014-01-31T00:00:00.000Z</StatusDate><Source id="1534352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2014-01-31T00:00:00.000Z</StatusDate><Source id="1534352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2015-02-06T00:00:00.000Z</StatusDate><Source id="1655471" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2015-02-06T00:00:00.000Z</StatusDate><Source id="1655471" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2015-02-06T00:00:00.000Z</StatusDate><Source id="1655471" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2015-02-06T00:00:00.000Z</StatusDate><Source id="1655471" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2012-05-03T00:00:00.000Z</StatusDate><Source id="1232776" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2014-05-30T00:00:00.000Z</StatusDate><Source id="1954913" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2014-03-31T00:00:00.000Z</StatusDate><Source id="1534352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2014-10-30T00:00:00.000Z</StatusDate><Source id="1954913" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2014-03-31T00:00:00.000Z</StatusDate><Source id="1534352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2014-03-31T00:00:00.000Z</StatusDate><Source id="1534352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2014-03-31T00:00:00.000Z</StatusDate><Source id="1534352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2012-05-03T00:00:00.000Z</StatusDate><Source id="1232776" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2014-03-31T00:00:00.000Z</StatusDate><Source id="1534352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2015-06-19T00:00:00.000Z</StatusDate><Source id="1655471" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2015-06-19T00:00:00.000Z</StatusDate><Source id="1655471" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2015-06-19T00:00:00.000Z</StatusDate><Source id="1655471" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2014-03-31T00:00:00.000Z</StatusDate><Source id="1534352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2014-03-31T00:00:00.000Z</StatusDate><Source id="1534352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate>2014-03-31T00:00:00.000Z</StatusDate><Source id="1534352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2015-06-19T00:00:00.000Z</StatusDate><Source id="1655471" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2014-07-25T00:00:00.000Z</StatusDate><Source id="1579001" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2014-07-25T00:00:00.000Z</StatusDate><Source id="1579001" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2014-07-25T00:00:00.000Z</StatusDate><Source id="1579001" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2014-07-25T00:00:00.000Z</StatusDate><Source id="1579001" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2014-07-25T00:00:00.000Z</StatusDate><Source id="1579001" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01207"><Name>PIM-3 protein kinase</Name><SwissprotNumbers><Swissprot>O70444</Swissprot><Swissprot>P58750</Swissprot><Swissprot>Q86V86</Swissprot><Swissprot>Q91822</Swissprot><Swissprot>Q9PU85</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01569"><Name>PIM protein kinase</Name><SwissprotNumbers/></Target><Target id="PTGT-01570"><Name>PIM-1 protein kinase</Name><SwissprotNumbers><Swissprot>P06803</Swissprot><Swissprot>P11309</Swissprot><Swissprot>P26794</Swissprot><Swissprot>Q95LJ0</Swissprot><Swissprot>Q9N0P9</Swissprot><Swissprot>Q9YHZ5</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01571"><Name>PIM-2 protein kinase</Name><SwissprotNumbers><Swissprot>Q62070</Swissprot><Swissprot>Q9P1W9</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2004756" linkType="reference" linkID="2004756"&gt;2004756&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>C[C@H]1C[C@H](C[C@H](C1)N)c2ccncc2NC(=O)c3ccc(c(n3)c4c(cccc4F)F)F</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="2699485" number="WO-2010026124" title="Picolinamide derivatives as kinase inhibitors"/><PatentFamily id="2949425" number="WO-2015081083" title="Combination therapy comprising an inhibitor of JAK, CDK and PIM"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>